CRC Research Update — September 03, 2026
Today's colorectal cancer research highlights
crc-research
A collection of 715 issues
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
Skip to content
The CRC Digest
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology)
This content is informational only and does not constitute
Screening Age Thresholds Miss Early-Onset CRC Risk Established in Youth
Skip to content
The CRC Digest
Screening Age Thresholds Miss Early-Onset CRC Risk Established in Youth
A new analysis argues that age-based screening creates a "blind spot" for early-onset colorectal cancer because high-risk states may be established through early-life exposures decades before screening begins at age 45. (Frontiers
Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC
A population-based multicenter study examined real-world outcomes of the targeted therapy combination encorafenib plus panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. (Clinical Colorectal Cancer)
This content is informational only and
Computer-Aided Feedback System Evaluated for Colonoscopy Quality in Denmark
Skip to content
The CRC Digest
▪ SCREENING
Computer-Aided Feedback System Evaluated for Colonoscopy Quality in Denmark
A stepped-wedge cluster-randomised trial across three Danish hospitals evaluated the effect of a computer-aided quality feedback and monitoring system on endoscopists' adenoma detection rate in patients aged 50-74 with positive FIT results. (The
Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC
Skip to content
The CRC Digest
▸ TREATMENT
Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC
An international retrospective study of dMMR/MSI-H metastatic colorectal cancer patients found that immune checkpoint blockers produced durable responses even in patients with poor ECOG performance status, a group often excluded
Immunotherapy Compared to Standard Care in MSS Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Immunotherapy Compared to Standard Care in MSS Metastatic CRC
A propensity-matched analysis of 708 chemorefractory patients compared immune checkpoint inhibitors to standard treatments like trifluridine/tipiracil in microsatellite stable metastatic colorectal cancer, though ICIs have limited efficacy in this population and selected patients
CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights
Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients
Skip to content
The CRC Digest
◇ RESEARCH
Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients
A prospective multicenter registry enrolled consecutive, unselected patients with primary colorectal adenocarcinoma at six Moscow centers between 2022 and 2025 to establish population-level data on mismatch repair deficiency prevalence
Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC
Skip to content
The CRC Digest
◇ RESEARCH
Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC
Researchers used single-cell RNA sequencing to compare PD-1-resistant and PD-1-sensitive MSI-H metastatic colorectal tumors, identifying a gene regulatory network involving ETV4 and MC1R that may explain why some MSI-H cancers don'